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ABSTRACT

A method for preparing a stable dispersion of a camptothecin,
camptothecin prodrug, or analog thereof for administration to
a patient in need thereof includes preparing a solution of the
camptothecin, Wherein the solution has a pH Which places
substantially an entirety of that camptothecin in a carboxylate
form. The camptothecin may be a neutral camptothecin. The
solution is next loaded into a liposome including at least one

lipid, Which may be a phospholipid. An intraliposomal pH is
maintained Which preserves substantially an entirety of the

camptothecin in the carboxylate form. The liposomal disper
sion is administered to an individual in need thereof, Whereby
the liposomes accumulate at and permeate into tumor tissue
and an active, lactone form camptothecin is released in situ at
the tumor site. Compositions formulated in accordance With
the described method for treatment of a cancer in an animal in

need thereof are provided also.

24 Claims, 3 Drawing Sheets
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2
It is knoWn to utilize liposomes as delivery vehicles for

LIPOSOMAL, RING-OPENED
CAMPTOTHECINS WITH PROLONGED,

camptothecins. Liposomal encapsulation can improve solu
bility of both neutral and cationic camptothecins, overcoming
knoWn Water insolubility of camptothecins and analogs and
also minimizing side effects of camptothecins relating to their
cytotoxicity by more closely targeting delivery to tumor tis

SITE-SPECIFIC DELIVERY OF ACTIVE
DRUG TO SOLID TUMORS

This invention Was made With Government support under
NIH/NCI Grant R0l-CA-8706l. The Government may have

sue. In addition, it has been shoWn that liposomes may accu
mulate in tumor tissue after delivery due to an enhanced

certain rights in this invention.

permeation and retention effect ((Drummond, D. C., Meyer,
O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. 1999,

TECHNICAL FIELD

Optimizing liposomes for delivery of chemotherapeutic
The present invention relates to the ?eld of compositions

agents to solid tumors, Pharmacol. Rev. 51(4): 691-743)),
providing a more targeted drug delivery and enabling passive
tumor targeting. That is, drug encapsulation in liposomes can
improve drug distribution (preferentially to tumor tissue
rather than normal tissue) by reducing drug access to normal
tissue. Speci?cally, the enhanced permeability of the
microvasculature in tumor tissue alloWs particles having the

for treatment of a cancer in an animal, and to methods for

preparing such compositions. In particular, the present inven
tion relates to a method for formulating a stable liposomal

camptothecin or analog thereof, and to compositions formu

lated thereby.
BACKGROUND OF THE INVENTION
20

Structure-activity studies shoW that successful inhibition

such as liposomes are retained in tumor tissue for an increased

of DNA topoisomerase I by camptothecin analogues requires
an intact lactone ring (E-ring) functionality. Camptothecin

period of time.
Camptothecins in the active lactone form partition prefer

analogs having open lactone ring structures (also knoWn as
the carboxylate form or as camptothecin carboxylates) are

entially into liposomal membranes, thus minimizing expo
25

poorly accumulated by cancer cells, exhibit limited activity
against the topoisomerase enzyme, and may be more toxic to
healthy cells than the lactone form.

Unfortunately, in aqueous solutions, camptothecins
undergo a pH dependent hydrolysis to the inactive carboxy
late form (FIG. 1). This, coupled With the fact that the inactive
carboxylate form is favored in aqueous solution at pH 7.4 may

30

sure to the aqueous environment and decreasing unWanted
conversion of the active lactone form to the inactive carboxy
late form. For this reason, typically a loW intraliposomal pH is
maintained to stabilize camptothecins held therein in the
active lactone form. This formulation strategy typically
requires use of an aqueous buffer and, While effective for

cationic camptothecins, is unsuitable for neutral camptoth
ecins due to their reduced Water-solubility at loW pH as noted

above. Accordingly, While liposomal delivery technology is

account for the limited clinical success of certain camptoth
ecins. Even more, under physiological conditions such as in

blood, this equilibrium may shift further toWard the inactive

size range of a liposome to escape from the blood circulature
and collect in tumor tissue. Once in the tumor bed, particles

35

an effective method of delivery for camptothecins, presently
it is less suited to delivery of neutral camptothecins due to the

carboxylate form by preferential carboxylate binding to

di?iculties in achieving adequate concentrations of liposome

serum albumin, Which affects certain congeners more than

bound drug, and also to inadequate retention of the lactone

others.
Camptothecins may be further subclassi?ed into neutral

form of the drug in liposomes after injection. Indeed, inad
equate retention of lactone-form neutral camptothecins in

and cationic camptothecins. Camptothecins Which exist pri

40

marily as neutral species at pH less than 7 are generally
classi?ed as neutral, Whereas camptothecins having cationic
substituent groups in the parent structure and Which exist

ventional dosage forms such as injectable solutions.

predominantly as positively charged species at pH less than 7
are classi?ed as cationic camptothecins. Both subspecies of

45

camptothecins undergo chemical degradation by lactone ring

Especially for the advantages provided by use of neutral
camptothecins compared to cationic camptothecins, that is,
enhanced membrane-binding and superior drug stability in
the presence of blood components such as albumin, there
remains a need in the art for pharmaceutical formulations

hydrolysis to the inactive carboxylate form as described
above. It is knoWn that neutral camptothecins are signi?cantly
less Water-soluble at loW pH than their cationic counterparts.

This poor Water-solubility has severely limited the types of
formulations and drug concentrations of highly lipophilic

liposomes after delivery to patients limits or eliminates any

advantage provided by liposomal delivery compared to con

comprising neutral camptothecins for treatment of various
cancers. Such formulations should provide a stable camptoth
50

neutral camptothecinsm, prodrugs and analogs [e.g., l0-hy
droxy-7-ethyl camptothecin (SN38), silatecan 7-t-butyldim

ecin formulation, and also improve retention of intraliposo
mal drug, promoting passive targeting of tumor tissue by
liposomes and delivery of increased dosages of drug to such
tumor tissue While reducing effects on healthy tissue.

ethylsilyl-l0-hydroxycamptothecin (DB-67), karenitecan,
gimatecan, irinotecan, 9-nitro camptothecin, and the like] that

55

SUMMARY OF THE INVENTION

can be employed for clinical treatment of cancer, even though

lipophilic camptothecins and analogs provide several impor

In accordance With the foregoing identi?ed need, a novel
method for preparing a liposomal formulation of a camptoth

tant advantages over their Water-soluble counterparts. For

example, because of its increased lipophilicity and dual

7-alkylsilyl and l0-hydroxy substitution, DB-67 displays

ecin, prodrug, or analog thereof, and compositions formu
60

superior binding to cellular and liposomal membranes and

lated thereby, are provided. In one aspect, a method is pro

vided for preparing a stable dispersion of a camptothecin,
prodrug, or analog thereof for delivery to a patient in need

enhanced drug stability in the presence of human serum albu

min When compared With clinically relevant, more hydro

thereof. The method includes preparing a solution of a camp

philic camptothecin analogues. Indeed, in vitro cytotoxicity

tothecin, prodrug, or analog thereof, Wherein the solution has
a pH Which places substantially an entirety of that camptoth
ecin, prodrug, or analo g thereof in substantially a ring-opened
carboxylate form. Next, the solution is loaded into a liposome

assays indicate that DB-67 has at least comparable potency

With other FDA approved camptothecin analogs (e.g., Camp
tosar and Hycamtin).

65
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having an intraliposomal pH Which preserves substantially an
entirety of the intraliposomal camptothecin, prodrug, or ana
log thereof in the ring-opened, carboxylate form. Next is the
step of delivering the liposome to a patient in need thereof,

embodiments and its several details are capable of modi?ca

tion in various, obvious aspects all Without departing from the
invention. Accordingly, the draWings and descriptions Will be
regarded as illustrative in nature and not as restrictive.

Whereby the liposome accumulates at a tumor site and the
camptothecin, prodrug or analog thereof is released as an
active, lactone form in situ at the tumor site.

BRIEF DESCRIPTION OF THE DRAWING

The solution of camptothecin, prodrug, or analog thereof
may be formulated to have a pH of from about 9.0 to about
11.0. In one aspect of the invention, a neutral camptothecin,

The accompanying draWing incorporated in and forming a
part of the speci?cation illustrates several aspects of the
present invention and, together With the description, serves to
explain the principles of the invention. In the draWing:
FIG. 1 depicts the reversible lactone ring-opening reaction

prodrug, or analog thereof is utiliZed, including Without limi

tation camptothecin, DB-67, SN-38, gimatecan, karenitecin,
irinotecan, 9-nitro camptothecin, and mixtures thereof.
The liposome Will typically be formulated to include at

in camptothecins;

least one lipid, typically selected from at least one of a phos

pholipid and/or a sterol, for example cholesterol. The lipo

FIG. 2 shoWs liposomal release of DB-67 in aqueous solu
tion at pH 4 vs. pH 9.5; and
FIG. 3 shoWs liposomal release of DB-67 in plasma at pH

some may further include a sphingolipid. That phospholipid
may be a synthetic or a natural phospholipid, and may be an

egg phospholipid, a soy phospholipid, distearoylphosphati

dyl choline, dipalmitoylphosphatidyl choline, diarachi
donoyl phosphatidyl choline, hydrogenated soy phosphatidyl

4.5 vs. pH 9.5.
20

Reference Will noW be made in detail to the presently

preferred embodiments, examples of Which are illustrated in

choline, dimyristoylphosphatidyl glycerol, dioleylphosphati
dylglycerol, dimyristoylphosphatidylcholine, phosphatidyl

the accompanying draWing.

choline, pho sphatidyl ethanolamine, and any mixture thereof.
Optionally, the liposome may be prepared from a mixture of
phospholipids including from about 5% to about 10% of a

25

DETAILED DESCRIPTION OF THE INVENTION

pegylated phospholipid. In one embodiment, the liposome
As summarized above, described herein are novel methods

may include from about 70% to about 95% (W/v) of a ?rst
phospholipid and from about 5% to about 10% (W/v) of a

second, pegylated phospholipid. The chain length of the ?rst

30

tions formulated thereby. It Will be understood that the term
camptothecin as used herein is intended to refer collectively

phospholipid may be selected to be substantially the same as

the chain length of the second, pegylated phospholipid.
In another aspect, a method is provided for administering a
stable dispersion comprising a neutral camptothecin or ana
log thereof to an animal, including a human, in need thereof.
The method is substantially as described above, With the

to various camptothecins, camptothecin prodrugs, and camp
tothecin analogs as are Well knoWn in the art. The methods
35

and compositions described herein may be accomplished by
various means Which are illustrated in the examples beloW.
These examples are intended to be illustrative only, as numer
ous modi?cations and variations Will be apparent to those
skilled in the art.

further step of separating liposomes containing entrapped
neutral camptothecins, prodrugs, or analogs thereof from any

free drug before administering the liposome preparation. The
liposome is then delivered to a patient in need thereof,
Whereby the liposome accumulates at a tumor site and the

for providing liposomal formulations of camptothecins,
camptothecin prodrugs, and analogs thereof, and composi

40

It is knoWn that at pH ranges Which favor the lactone-form

camptothecin, during liposomal encapsulation the drug pref

neutral camptothecin, prodrug, or analog thereof is released

erentially partitions into liposomal membranes. This mini

as an active, lactone form in situ at the tumor site.

miZes exposure to the aqueous environment, resulting in a

In yet another aspect, a composition providing a therapeu
tically su?icient amount of a camptothecin, prodrug, or ana

45

log thereof, Which may be a neutral camptothecin, for the
treatment of a cancer in an animal, including a human, in need

the active lactone form. HoWever, this strategy requires use of
an aqueous buffer to dissolve the drug prior to preparation of

thereof is provided. The camptothecin, prodrug, or analog
thereof is loaded into a liposome having an intraliposomal pH
suf?cient to maintain substantially an entirety of the intrali

liposomes by conventional hydration-extrusion, sonication,
50

posomal neutral camptothecin, prodrug, or analog thereof in
a carboxylate form. The methods for loading the camptoth
ecin, prodrug, or analog into the liposome and the lipids and
drugs suitable for preparing the composition, are substan
tially as described above. The composition may be formu

decrease in ring opening of the active lactone. Accordingly,
conventional liposomal formulations for camptothecins
employ a loW pH in liposomes to stabiliZe camptothecins in

or drug-lipid ?lm techniques. Because of the loW Water-solu

bility of neutral camptothecins and the concomitant reduc
tions in retention time for liposomal formulations of neutral

camptothecins (see Table 1), such conventional strategies are
more favorable to liposomal encapsulation of cationic camp
55

tothecins than neutral camptothecins.

lated for delivery to a patient in need thereof, such as in an

injectable formulation. Upon such delivery, the liposome
comprising entrapped drug accumulates at and permeates
into a tumor site. Over time, the camptothecin, prodrug or
analog thereof is released as an active, lactone form in situ at
the tumor site.

TABLE 1
Percent retention vs. circulation time for investigational

liposomal camptothecins

60

% retention

Other objects and applications of the present invention Will
become apparent to those skilled in this art from the folloWing
description Wherein there is shoWn and described a preferred

embodiment of this invention, simply by Way of illustration of
the modes currently best suited to carry out the invention. As

it Will be realiZed, the invention is capable of other different

65

Camptothecin

Status

4 hr

Lultotecanl

Phase 11

~50

Topotecan2

Preclinical

23

Irinotecan3

Preclinical

68*

24 hr
<0.1

~0
8*

US 8,067,432 B2
5

6

TABLE l-continued

Hank’s solution, Ringer’s solution, or physiological saline
buffer. Pharmaceutical formulations intended for parenteral
injection, e.g., by bolus injection or continuous infusion, may
be provided in unit dosage form, e.g., in ampoules or in

Percent retention vs. circulation time for investigational

liposomal carnptothecins

multi-do se containers, typically with an added preservative as
set forth above.

% retention

Carnptothecin

Status

4 hr

24 hr

DB-674
SN-3 85

Preclinical
Phase r/n

<1
<1

ND
<0.1

EXAMPLES

Set forth in greater detail below are speci?c details related
to selected modes for carrying out the methods and compo
sitions of the present invention. The examples set forth herein

lEmerson et al., 2000, Antitumor e?icacy, pharmacokinetics, and biodistribution of
N'X-211: A low-clearance liposomal formulation of lurtotecan. Clin. Canc. Res. 6: 2903

2912; Colbern et al., 1998, Encapsulation of the topoisomerase I inhibitor GL147211C in
pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon
tumor xenogra?s, Clin. Canc. Res. 4: 3077-3082.

are in no way intended to limit the scope of the invention.

2Tardi et al., 2000, Liposomal encapsulation oftopotecan enhances anticancer e?icacy in

4Zamboni et al., 2005, Plasma and tissue disposition ofnon-liposomal DB-67 and liposomal
DB-67 in CB-17 SCID mice. Investigational New Drugs, published on-line February 2008

Those of skill in the art will realiZe that, given the teachings
provided herein, many variations of the methods are possible
that will fall within the scope of the present invention. Unless
otherwise indicated, all citations of literature are speci?cally

(DOI10.1007/s10637-007-9109-9).

incorporated by reference herein in their entirety.

murine and human xenogIaft models. Cancer Res. 60: 3389-3393.

3Messerer et al., 2004, Liposomal irinotecan: formulation development and therapeutic
assessment in murine xenogra? models of colorectal cancer, Clin. Canc. Res. 10: 6638
6649.

Pal et al., 2005, Preclinical safety, pharmacokinetics and antitumor e?icacy pro?le of
liposome-entrapped SN-38 formulation, Anticancer Res. 25: 331-341.

Camptothecins, including neutral camptothecins, exist

20

predominantly in the active lactone form in aqueous solution

Phospholipids and pegylated phospholipids were pur
chased as powders fromAvanti Polar Lipids (Alabaster, Ala.).
A representative neutral camptothecin, DB-67, was from

at pH less than 6.0, whereas the inactive carboxylate species
dominates in aqueous solution at pH above 6.0. At physi

ological pH (7.4), approximately 70% of camptothecin is in
the carboxylate form. Thus, in plasma, approximately 70% of
the drug is in carboxylate (inactive) form and 30% in lactone
(active) form. The half-life of lactone-form camptothecin in
rat plasma is approximately 40 min. Encapsulating the lac
tone form of a representative neutral camptothecin, DB-67, in

Example 1

Novartis Pharmaceutical Corp. (East Hanover, N.J.). Spra
gue-Dawley rat plasma was from Bioreclamation, Inc. (East

Meadow, N.Y.). CENTRICON® (MWCO: 100000) centrifu
gal ?lter devices from Millipore (Billerica, Mass.) and
SEPHADEX® G-25 M prepacked siZe exclusion columns
30

(GE Healicare Bio-sciences Corp., Piscataway, NJ.) were

pegylated liposomes at low pH (4) prolongs the half-life of

used in liposome studies. All other reagents were from Fisher

the drug. However, at this pH it was not possible to retain the
drug in liposomes in aqueous buffers for long periods of time.
It has been found that preparing liposomes containing

Scienti?c (Florence, Ky).

entrapped camptothecins, prodrugs, or analogs thereof,

35

including neutral camptothecins, at a pH su?icient to keep
substantially an entirety of the intraliposomal drug in the
inactive carboxylate form signi?cantly increased the half-life
for retention in liposomes. This is because the release of the

carboxylate form from the liposomes is negligible. Surpris
ingly, however, slow conversion of the entrapped, ring
opened carboxylate occurs, providing a low, steady-state con
centration of lactone form drug which is then slowly released
from the liposome. Thus, the present invention provides a
slow and prolonged release of the active lactone form from
the liposome. This release rate can be varied by changing the
intraliposomal pH. That is, an increase in the intraliposomal
pH slows the release of active lactone from the liposome, and

50 to about 300 nm are contemplated for use in the present

invention. Methods for preparing liposomes falling within a
40

predetermined siZe range are known in the art (see Drum

45

mond et al., 1999).
For the hydration-extrusion technique, ?lms of the desired
lipid mixtures were prepared in test tubes by dissolving
weighed amounts of lipids in chloroform, evaporating the
solvent under nitrogen, and drying overnight in vacuo. A
stock solution of drug (DB-67) in a buffer providing the
desired pH was added to hydrate the lipids, followed by
shaking and extrusion through polycarbonate membranes at
600 C. to obtain unilamellar vesicles containing entrapped

vice-versa.

The compositions contemplated herein may be formulated
for delivery to patients in need thereof using methods and

Liposomes were prepared by conventional hydration-ex
trusion technique. However, the skilled artisan will appreciate
that any suitable method for preparing liposomes having a
desired particle siZe and lamellarity is contemplated. In one
aspect, liposomes having a particle siZe range of from about

50

drug. Thus, intraliposomal pH of the ?nal liposome-en
trapped drug preparation prepared as described was substan
tially in accordance with the pH of the buffer/DB-67 solution
in which phospholipid mixtures were hydrated.

formulations well within the skill in the art. For example, the
compositions may be prepared for direct delivery, or as phar
maceutical formulations along with suitable carriers or
excipients as are well known to the skilled artisan. For
example, one or more additives may be included with the
compositions, such as one or more stabilizers, buffers, salts,

preservatives, ?llers, and the like. Suitable buffers include
without limitation phosphates, carbonates, citrates, and oth
ers. Suitable preservatives include without limitation EDTA,
EGTA, BHA, BHT, and others.
The skilled artisan will also readily appreciate that phar

55

The liposomal permeability of DB-67 in aqueous solution
was measured over a pH range of 4.5 to 9.5 using a dynamic

dialysis method [V. Joguparthi and B. D. Anderson, Liposo
60

maceutical formulations comprising the present composi
lations of the compositions may be provided as aqueous solu

tions, typically in physiologically compatible buffers such as

mal delivery of hydrophobic weak acids: Enhancement of
drug retention using a high intraliposomal pH, J. Pharm. Sci.
97, 433-454 (2008)]. Liposome-encapsulated DB-67 solu
tions were prepared at varying pH values as described above.

For liposome solutions at each pH evaluated, liposome-en

tions will be highly dependent on the route of administration

chosen. By way of non-limiting example, injectable formu

Example 2

65

trapped drug was separated from free drug by passing lipo
somes through a SEPHADEX® column followed by 5 mL of
the same buffer added in 1 mL increments. The liposome

US 8,067,432 B2
7

8

containing eluent Was dialyZed at 37° C. in the same buffer. At

form of the drug directly at the tumor site, providing a sig
ni?cant enhancement in ef?ciency of delivery.

intervals, 100 pl of liposome suspension Was removed from
the dialysis tube and added to 900 pl cold methanol/acetoni

Example 4

trile (2: 1, v/v). These samples Were dried under nitrogen and

stored (—25° C.) prior to analysis.
A 10 mg/ml solution of DB-67 Was prepared in pH 9.5
sodium carbonate buffer and ?ltered through a 0.2 pm syringe
?lter. The drug solution Was used to hydrate phospholipids
(DSPC+5 mol % m-PEG DSPE) With shaking at 60° C. to
form a 30 mg/ml suspension of multilamellar vesicles. The
suspension Was extruded through a high pressure extruder to

With reference to Table 2, DB-67 Was retained in lipo

somes (prepared by hydration-extrusion) in aqueous solution
for increased periods of time When liposomes Were prepared
at high pH. In aqueous solution, the half-life for retention of
DB-67 in liposomes increased from 3 hours at pH 4 to about
90 hours at pH 9.5. Without being restricted to any particular
theory, this may be due to conversion of DB-67 lactone to the

form unilamellar vesicles. The vesicles Were then cooled at
room temperature and stored beloW 5° C. until use. Prior to

carboxylate form in the intraliposomal space.

use, liposomes Were separated from unentrapped DB-67 by
passing through a gel ?ltration column Which Was pre-equili
brated With pH 7.4 phosphate buffered saline. 100 pl of lipo

TABLE 2
Half-life for liposome retention of DB-67 at various pH.

pH

t1/2 (hours)

4
7.21
7.78
8.36
8.95
9.49

3
3.8
5.4
32.9
57.9
91.9

somes collected from gel ?ltration Were immediately added
20

to 4 ml of plasma to study the release of liposome-entrapped
DB-67 carboxylate from plasma as described above. Samples
Were taken at various time intervals and DB-67 Was extracted

from 100 pl of plasma using 300 pl of ice-cold methanol
solution and acetonitrile (2: 1 v/v) at —9° C. The concentration
of DB-67 Was determined by HPLC as described above.
25

Example 5
As shoWn in FIG. 2, When intraliposomal pH Was main

tained Whereby the carboxylate species of DB-67 predomi
nated, release of the drug from liposomes Was negligible. For
release to occur, pH conditions alloWing formation of the
active, lactone species Were required.

30

Example 3
The e?iux of DB-67 from liposomes in plasma Was moni

35

tored. Aliquots of liposome suspension containing DB-67
added to plasma and incubated at 37° C. At intervals, an

aliquot of plasma Was WithdraWn, added to cold methanol/

collected from gel ?ltration Were immediately loaded into a
40

Example 6

Were prepared in acidi?ed methanol. All standards Were

A 20 mg/ml solution of DB-67 is prepared in pH 10.5
sodium carbonate buffer and ?ltered through a 0.2 pm syringe

diluted into the desired concentration range using cold metha
nol/acetonitrile (2:1 v/v). HPLC retention times Were 1.6 and

?lter. The drag solution is used to hydrate phospholipids
(DSPC+5 mol % m-PEG DSPE) With shaking at 60° C. to
50

somes Was 3.5 hours When intraliposomal pH Was 4.5 and 6.3

hours When intraliposomal pH Was 9.5. The half-life for
retention at intraliposomal pH 9.5 Was less in plasma than in
aqueous solution due to a decrease in intraliposomal pH
observed after adding liposomes to plasma. HoWever, even in

dialysis tube and dialyZed (37 C) against 1000 ml of pH 9.5
sodium carbonate buffer. DB-67 analysis Was by HPLC as
described above.

HPLC analyses used herein have been previously
described in detail (Joguparthi et al., 2006). DB-67 carboxy
late standards (10-100 nM) Were prepared in 10 mM carbon
ate buffer (pH 10.4). DB-67 lactone standards (5-30 nM)

5.2 min for DB-67 carboxylate and lactone, respectively.
FIG. 3 shoWs liposomal release of DB-67 in plasma at pH
4.5 and pH 9.5. In plasma, the half-life for retention in lipo

form unilamellar vesicles. The vesicles Were then cooled at
room temperature and stored beloW 5° C. until use. Prior to

use, liposomes Were separated from unentrapped DB-67 by
passing through a gel ?ltration column Which Was pre-equili
brated With pH 9.5 sodium carbonate buffer. The liposomes

(With unentrapped drug separated as described above) Were

acetonitrile (2:1 v/v), centrifuged (14000 rpm) and stored
froZen (—25° C.) for HPLC analysis.

A 10 mg/ml solution of DB-67 Was prepared in pH 9.5
sodium carbonate buffer and ?ltered through a 0.2 pm syringe
?lter. The drug solution Was used to hydrate phospholipids
(DSPC+5 mol % m-PEG DSPE) With shaking at 60° C. to
form a 30 mg/ml suspension of multilamellar vesicles. The
suspension Was extruded through a high pressure extruder to

form a 30 mg/ml suspension of multilamellar vesicles. The
suspension is extruded through a high pressure extruder to
form unilamellar vesicles. The vesicles are then cooled at
room temperature and stored beloW 5° C. until use. Prior to
use, liposomes are Warmed to room temperature and sepa

55

rated from unentrapped DB-67 by gel ?ltration as described.

plasma, preparing liposomes at pH 9.5 and maintaining
intraliposomal pH at levels Which preserve the carboxylate
form of the entrapped neutral camptothecin prolonged intrali
posomal retention. Thus, the potential for exposure of healthy
tissue to the drug Was reduced. This improved intraliposomal
retention enables the drug to remain in the liposomes While
they are circulating in the bloodstream. After the liposomes
collect in solid tumors due to their enhanced permeation
across the tumor vasculature and their improved retention

Within the tumor tissue (Drummond et al., 1999), the
entrapped drug Will be sloWly released as the active, lactone

Example 7
10 mg of DB-67 is added to 60 mg of a phospholipid
mixture in 2 ml of a 2:1 mixture of chloroform:ethanol. The

solution is evaporated under nitrogen to form a drug-lipid
?lm. The ?lm is hydrated With pH 10.5 carbonate buffer With
shaking to form multilamellar vesicles. The suspension is
extruded to form unilamellar vesicles. The vesicles are cooled

to room temperature and unentrapped drug is separated from
entrapped drug as described. The liposomes are then stored
beloW 5° C. until use.
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Example 8

is exchanged for a desired concentration of NaCl solution

With the proviso that intraliposomal pH is maintained the
Drug is loaded in vesicles as described in Examples 6 and
7, except the drug and phospholipids are dissolved in pure

same as that used in liposome preparation.

Example 20

chloroform, pure acetone, pure methanol, or a suitable com

bination of those solvents. Subsequently, solvent is evapo
rated to form a drug-lipid ?lm.

Unilamellar vesicles are prepared as described in

Examples 4-17, With the exception that during separation of
entrapped from unentrapped drug, the extraliposomal buffer

Example 9

is exchanged for a desired concentration of sucrose solution,
Unilamellar vesicles are prepared as described in

With the proviso that intraliposomal pH is maintained the

Examples 4-8 using pH 9.5 borate buffer.

same as that used in liposome preparation.

Example 10

Example 21

Unilamellar vesicles are prepared as described in

Unilamellar vesicles are prepared as described in

Examples 4-8 using pH 9.5 Tris-HCl buffer.

Examples 4-20, using a lipid mixture comprising 80% DSPC,
15% cholesterol, and 5% m-PEG DSPE.

Example 11
20

Unilamellar vesicles are prepared as described in

Examples 4-8 using pH 9.3 ammonium hydroxide.

Example 22
Unilamellar vesicles are prepared as described in

Examples 4-20, using a lipid mixture comprising 80% HSPC,

Example 12

15% cholesterol, and 5% pegylated PE.
25

Unilamellar vesicles are prepared as described in

Example 23

Examples 4-8 using pH 9 glycine.

Unilamellar vesicles are prepared as described in

Example 13
Unilamellar vesicles are prepared as described in

Examples 4-20, using a lipid mixture comprising 55% DSPC,
30

The skilled artisan Will readily appreciate that the present

Examples 4-12, With the exception that the vesicles are
formed by sonication rather than extrusion.

Example 14

40% cholesterol, and 5% m-PEG DSPE.
disclosure sets forth an ef?cient and ef?cacious method for
preparing a liposomal formulation of a camptothecin, in one

aspect being a neutral camptothecin, camptothecin prodrug,
35

Unilamellar vesicles are prepared as described in

Examples 4-13, except the drug used is SN-38.

Example 15
40

Unilamellar vesicles are prepared as described in

Examples 4-13, except the drug used is karenitecan.

or analog thereof. Advantageously, the compositions formu
lated by the present method provide a stable liposomal camp
tothecin in therapeutically effective amounts, Wherein the
drug is retained in the liposome under physiological condi
tions for increased periods of time. This alloWs accumulation
of the liposomal camptothecin formulations at a tumor site,
With limited side effects on healthy cells and tissue, and
further alloWs in situ delivery of the active lactone form of the
drug to directly to tumor tissue in adequate concentrations for
effective tumor cell killing and/ or groWth inhibition.

Example 16
45

By increasing intraliposomal pH and maintaining that pH
prior to administration and during in vivo delivery to a tumor

Unilamellar vesicles are prepared as described in

site, it has been surprisingly found that liposomal retention of
a camptothecin may be prolonged, reducing the potential for
exposure of healthy tissue to the drug When administered in

Examples 4-13, except the drug used is gimatecan.
Example 17
50

Unilamellar vesicles are prepared as described in

vivo. This improvement in retention alloWs the drug to accu
mulate at tumor tissue, i.e., an in vivo enhanced permeation

Examples 4-13, except the drug used is 9-nitro camptothecin.

and retention effect (Drummond et al., 1999). As the lipo

Example 18

somes accumulate Within the tumor tissue, over time the drug
is released as the lactone form in situ, thus achieving release
of drug in the active form directly at the tumor site, rather than

55

drug residing in the bloodstream at physiological conditions
favoring conversion to the inactive carboxylate form. Accord

Unilamellar vesicles are prepared as described in

Examples 4-17, With the exception that during separation of
entrapped from unentrapped drug, the extraliposomal buffer
is exchanged for pH 7.4 phosphate With the proviso that
intraliposomal pH is maintained the same as that used in

ingly, the problems of enhanced liposomal retention and
60

delivery of the active lactone form camptothecin to a tumor
site are simultaneously solved.

The foregoing description of preferred embodiments has

liposome preparation.

been presented for purposes of illustration and description. It

Example 19

is not intended to be exhaustive or limiting to the precise
forms disclosed. Obvious modi?cations or variations are pos

Unilamellar vesicles are prepared as described in

Examples 4-17, With the exception that during separation of
entrapped from unentrapped drug, the extraliposomal buffer

65

sible in light of the above teachings. The embodiments Were
chosen and described to provide the best illustration of the

principles described herein and their practical application to
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loading the solution of neutral camptothecin, camptothecin

thereby enable one of ordinary skill in the art to utilize the
invention in various embodiments and With various modi?

prodrug, or analog thereof into a liposome comprised of
at least one lipid, said liposome having an intraliposomal
pH Which preserves substantially an entirety of said

cations as are suited to the particular use contemplated. All
such modi?cations and variations are Within the scope of the

neutral camptothecin, camptothecin prodrug, or analog

invention as determined by the appended claims When inter
preted in accordance With the breadth to Which they are fairly,

thereof in the carboxylate form, said at least one lipid
being selected to provide to said liposome a net neutral
or anionic charge;

legally and equitably entitled.
What is claimed is:
1. A method for preparing a stable dispersion of a camp
tothecin or analog thereof for delivery to a patient in need

10

thereof, comprising:

analog thereof to a patient in need thereof Whereby the

preparing a solution of a camptothecin, camptothecin pro
drug, or analog thereof, said solution having a pH Which
places substantially an entirety of that camptothecin or

analog thereof in a carboxylate form;
loading the solution of camptothecin, camptothecin pro
drug, or analog thereof into a liposome comprised of at
least one lipid, said liposome having an intraliposomal
pH Which preserves substantially an entirety of said

separating the liposome from any free neutral camptoth
ecin, camptothecin prodrug, or analog thereof; and
administering the liposome loaded With said carboxylate
form neutral camptothecin, camptothecin prodrug, or
liposome accumulates at a tumor site and said neutral

camptothecin, camptothecin prodrug, or analog thereof
is released as an active, lactone form in situ at said tumor

site.
10. The method of claim 9, Wherein the solution of neutral

camptothecin, camptothecin prodrug, or analog thereof is
20

camptothecin, camptothecin prodrug, or analog thereof

formulated to have a pH of from about 8.0 to about 11.

11. The method of claim 9, Wherein the lipid is selected

in the carboxylate form, said at least one lipid being

from at least one of a phospholipid and a sterol.

selected to provide to said liposome a net neutral or

12. The method of claim 11, Wherein the phospholipid is

anionic charge; and
delivering said liposome loaded With said carboxylate form
camptothecin, camptothecin prodrug, or analog thereof
to a patient in need thereof, Whereby said liposome

selected from the group consisting of an egg phospholipid, a
25

toylphosphatidyl glycerol, dioleylphosphatidylglycerol,
dimyristoylphosphatidylcholine, phosphatidyl choline, phos

accumulates at a tumor site and said camptothecin,

camptothecin prodrug, or analog thereof is released as
an active, lactone form in situ at said tumor site.

soy phospholipid, distearoylphosphatidyl choline, dipalmi
toylphosphatidyl choline, diarachidonoyl phosphatidyl cho
line, hydrogenated soy phosphatidyl choline, dimyris

30

phatidyl ethanolamine, and mixtures thereof.

2. The method of claim 1, Wherein the solution of camp

13. The method of claim 9, Wherein said liposome com

tothecin, camptothecin prodrug, or analog thereof is formu

prises a mixture of phospholipids including from about 5% to
about 10% of a pegylated phospholipid.

lated to have a pH of from about 8.0 to about 11.0.

3. The method of claim 1, Wherein the lipid is selected from
at least one of a phospholipid and a sterol.

35

4. The method of claim 3, Wherein the phospholipid is

14. The method of claim 12, Wherein said liposome com
prises from about 70% to about 95% (W/v) of a ?rst phospho
lipid and from about 5% to about 10% (W/v) of a second,

selected from the group consisting of an egg phospholipid, a

pegylated phospholipid.

soy phospholipid, distearoylphosphatidyl choline, dipalmi
toylphosphatidyl choline, diarachidonoyl phosphatidyl cho
line, hydrogenated soy phosphatidyl choline, dimyris

15. The method of claim 14, Wherein a chain length of the
?rst phospholipid is substantially the same as a chain length
40

toylphosphatidyl glycerol, dioleylphosphatidylglycerol,
dimyristoylphosphatidylcholine, phosphatidyl choline, phos

16. The method of claim 9, Wherein the neutral camptoth
ecin, camptothecin prodrug, or analog thereof is selected
from the group consisting of camptothecin, DB-67, SN-38,

phatidyl ethanolamine, and mixtures thereof.
5. The method of claim 1, Wherein said liposome comprises
a mixture of phospholipids including from about 5% to about
10% of a pegylated phospholipid.

of the second, pegylated phospholipid.

gimatecan, karenitecin, irinotecan, 9-nitro camptothecin, and
45

mixtures thereof.

6. The method of claim 4, Wherein said liposome comprises

17. A composition comprising a therapeutically suf?cient
amount of a camptothecin, camptothecin prodrug, or analog

from about 70% to about 95% (W/v) of a ?rst phospholipid
and from about 5% to about 10% (W/v) of a second, pegylated

thereof, said camptothecin, camptothecin prodrug, or analog

phospholipid.

thereof for the treatment of a cancer in an animal in need
50

7. The method of claim 6, Wherein a chain length of the ?rst
phospholipid is substantially the same as a chain length of the

second, pegylated phospholipid.
8. The method of claim 1, Wherein the camptothecin,
camptothecin prodrug or analog thereof is selected from the

Wherein said liposome is comprised of lipids Whereby said
55

group of neutral camptothecins, camptothecin prodrugs, and

mal pH is from about 8.0 to about 11.0.

19. The composition of claim 7, Wherein the liposome

can, irinotecan, karenitecin, 9-nitro camptothecin, and mix

comprises at least one of a phospholipid and a sterol.
60

camptothecin, camptothecin prodrug, or analog thereof to a

20. The composition of claim 19, Wherein the phospholipid
is selected from the group consisting of an egg phospholipid,

patient in need thereof, comprising:

a soy phospholipid, distearoylphosphatidyl choline, dipalmi

toylphosphatidyi choline, diarachidonoyl phosphatidyl cho
line, hydrogenated soy phosphatidyl choline, dimyris

preparing a solution of a neutral camptothecin, camptoth
ecin prodrug, or analog thereof, said solution having a

pH Which places substantially an entirety of that neutral
camptothecin, camptothecin prodrug, or analog thereof
in substantially a carboxylate form;

liposome has a net neutral or anionic charge.

18. The composition of claim 17, Wherein the intraliposo

analogs consisting of camptothecin, DB-67, SN-38, gimate
tures thereof.
9. A method for administering a stable solution of a neutral

thereof being loaded into a liposome having an intraliposo
mal pH suf?cient to maintain substantially an entirety of the
intraliposomal camptothecin, camptothecin prodrug, or ana
log thereof in a carboxylate form for delivery to said animal,

65

toylphosphatidyi glycerol, dioleylphosphatidylglycerol,
dimyristoylphosphatidylcholine, phosphatidyl choline, phos
phatidyl ethanolamine, and mixtures thereof.
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21. The composition of claim 19, wherein the liposome
comprises a mixture of phospholipids including from about

24. The composition of claim 17, Wherein the camptoth
ecin, camptothecin prodrug, or analog thereof is selected
from the group of neutral camptothecins, camptothecin pro

5% to about 10% of a pegylated phospholipid.

22. The composition of claim 21, Wherein the liposome
comprises from about 70% to about 95% (W/V) of a ?rst
phospholipid and from about 5% to about 10% (W/V) of a

second, pegylated phospholipid.
23. The composition of claim 22, Wherein a chain length of
the ?rst phospholipid is substantially the same as a chain

length of the second, pegylated phospholipid.

drugs, and analogs consisting of camptothecin, DB-67,
SN-38, gimatecan, karenitecin, irinotecan, 9-nitro camptoth
ecin, and mixtures thereof.

